Discontinuing Crizotinib treatment

Abstract e20610 is from Canada and covers 97 patients. Post Crizotinib treatment 43% received Ceritinib, 20% received chemo and 37% received no additional treatment. Median overall survival was:

0.9 months for those who received no additional treatment,

7.6 months for those who received chemo, and

20.4 months for those received Ceritinib.

This entry was posted in ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply